CX3CR1+T Cell Predict Immunotherapy Efficacy
NCT06054152
·
clinicaltrials.gov ↗
COMPLETED
Status
150
Enrollment
OTHER
Sponsor class
Conditions
Non-small Cell Lung Cancer
Interventions
DRUG:
PD-1 inhibitor based immunotherapy
Sponsor
Shanghai Pulmonary Hospital, Shanghai, China